[Systemic adjuvant therapy in patients with operable breast cancer].
The results of adjuvant trials conducted from April, 1972 to August, 1978 showed that chemotherapy was more effective to premenopausal patients and endocrine therapy prolonged disease-free survival of postmenopausal patients compared with premenopausal ones. Preliminary analysis of randomized trial now on going suggests that endocrine therapy is best candidate for receptor-positive patients and chemotherapy for receptor-negative patients. Prognostic factors of primary breast cancer was discussed.
Tashiro
H
H
Nomura
Y
Y
Hisamatsu
K
K
D000732:Androstanols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D011184:Postoperative Period; D011379:Prognosis
D000732:Androstanols; D004965:Estrogen Antagonists; D008937:Mitomycins; D016685:Mitomycin; C006242:mepitiostane